OMedLive

CME Speakers

 

  • Eileen M. O'Reilly, MD

    Eileen M. O'Reilly, MD

    Eileen M. O'Reilly, MD

    Attending Physician, Member

    Eileen M. O’Reilly, MD, is associate director for clinical research for the David M. Rubenstein Center for Pancreatic Cancer Research, attending physician and member at Memorial Sloan-Kettering Cancer Center (MSKCC), and professor of medicine at Weill Medical College of Cornell University in New York. Her research initiatives include integrating molecular and genetic-based therapies for the treatment of pancreatic cancer, along with developing adjuvant and neoadjuvant therapies and identifying biomarkers that may be used to select therapy. Dr O’Reilly is the principal investigator of multiple phase I, II and III trials in pancreatic cancer, and has authored/co-authored multiple articles, editorials, and book chapters. She received her MD at Trinity College (Dublin University) in Ireland.
  • Andrea Wang-Gillam, MD, PhD

    Andrea Wang-Gillam, MD, PhD

    Andrea Wang-Gillam, MD, PhD

    Associate Professor, Department of Medicine

    Andrea Wang-Gillam received MD and PhD from University of Arkansas for Medical Science (UAMS). She completed the intern year at Cleveland Clinic Foundation, OH, and internal medicine residency and hematology/oncology fellowship training in UAMS, Dr. Wang-Gillam joined the Division of Oncology at Washington University in St. Louis in 2007, and she is an associate professor and clinical director of the Gastrointestinal Oncology Program there. Dr. Wang-Gillam’s research interest is in the area of novel therapy development in pancreatic cancer, and she is a principal investigator for multiple clinical studies in pancreatic cancer.
  • Matthew H. Kulke, MD, MMSc

    Matthew H. Kulke, MD, MMSc

    Matthew H. Kulke, MD, MMSc

    Associate Professor of Medicine

    Matthew Kulke, MD, MMSc, is director of the Neuroendocrine and Carcinoid Tumor Program at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School in Boston, Massachusetts. Dr Kulke has played a leading role in the molecular characterization of neuroendocrine tumors and in developing new treatments for this indication, including sunitinib, temozolomide everolimus, and telotristat ethyl. He serves on the gastrointestinal cancer committee for the Cancer and Leukemia Group B, the advisory board for the European Neuroendocrine Tumor Society, and chairs the neuroendocrine tumor guidelines panel for the National Comprehensive Cancer Network. He received his MD from the University of California, San Francisco School of Medicine and his MMSc from Harvard Medical School.
  • David C. Metz, MBBCh

    David C. Metz, MBBCh

    David C. Metz, MBBCh

    Professor of Medicine

    David C. Metz, MBBCh, is a professor of medicine and associate chief for clinical affairs in the Division of Gastroenterology at the University of Pennsylvania in Philadelphia, where he is director of the Acid-Peptic Disease Program and co-director of the GI Physiology Laboratory, the Swallowing Disorders Program and the Neuroendocrine Tumor Program. His clinical research investigates Zollinger-Ellison syndrome, H. pylori infection, nonsteroidal anti-inflammatory drug gastropathy, and gastroesophageal reflux disease. He has expertise in the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. Dr Metz earned his MBBCh (MD equivalent) from the University of the Witwatersrand in Johannesburg, South Africa.
  • Wen Wee Ma, MBBS

    Wen Wee Ma, MBBS

    Wen Wee Ma, MBBS

    Senior Associate Consultant, Medical Oncology

    Wen Wee Ma, MBBS, is a senior associate consultant in the Division of Medical Oncology at Mayo Clinic, Rochester, Minnesota. He is a board-certified medical oncologist with expertise in gastrointestinal oncology and developmental therapeutics. His research focuses on early phase anti-cancer drug development, and the application in gastrointestinal malignancies, including colorectal and pancreatic cancers. Prior to joining Mayo Clinic in 2016, he was an associate professor of oncology and directed the gastrointestinal cancers drug development program at Roswell Park Cancer Institute in Buffalo, New York. He has authored and co-authored over 50 publications, including those in high impact journals such as New England Journal of Medicine and Journal of Clinical Oncology.
  • Joleen M. Hubbard, MD

    Joleen M. Hubbard, MD

    Joleen M. Hubbard, MD

    Assistant Professor of Oncology

    Joleen M. Hubbard, MD, is assistant professor of medical oncology at Mayo Clinic in Rochester, Minnesota, where is also the chair of the Gastrointestinal Tumor Group Practice. She specializes in the treatment of gastrointestinal cancers, focusing on her area of clinical research, colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology, with a special interest in clinical and biologic markers of frailty. She is a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. She earned her MD from University of Minnesota Medical School.
  • Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Jennifer Saggio, MSN, CRNP, CPON

    Neuroblastoma Developmental Therapeutics Advanced Practice Nurse

    Jennifer Saggio received her graduate degree from the University of Pennsylvania’s School of Nursing. She has been a Nurse Practitioner at The Children’s Hospital of Philadelphia for the past 17 years. Over the past 9 years she has been part of the Neuroblastoma Developmental Therapeutics Team specializing in the care of children with relapsed and refractory Neuroblastoma.
  • Navin Pinto, MD

    Navin Pinto, MD

    Navin Pinto, MD

    Associate Professor of Pediatrics

    Navin R. Pinto, MD, is an attending physician at Seattle Children's Hospital and an associate professor of pediatrics at the University of Washington School of Medicine. Dr Pinto’s interests and expertise focus on the use of genetic sequencing technologies to develop more personalized treatment strategies (pharmacogenomics) for children, adolescents, and young adults with solid tumors. He is an active member in numerous professional societies, has authored or co-authored articles published in various peer-reviewed journals, and is involved in several Phase I trials at Seattle Children’s Hospital. He earned his medical degree from the St. Louis University School of Medicine, and completed his pediatrics residency and pediatric hematology-oncology fellowship at the University of Chicago.
  • Jason Shohet, MD

    Jason Shohet, MD

    Jason Shohet, MD

    Associate Professor of Pediatric Hematology and Oncology

    Jason Shohet, MD, PhD, is the research co-director, Neuroblastoma Program, at Texas Children’s Cancer Center and associate professor, Department of Pediatrics, Section of Hematology-Oncology at Baylor College of Medicine, both in Houston. Dr Shohet’s research focuses on developing better molecular targeted therapies for neuroblastoma and other solid tumors, with specific interest in cancer stem cell biology, cellular reprogramming/epigenetics, microRNA function as oncogenes and tumor suppressors, novel tumor markers, molecular targeted therapies for neuroblastoma and solid tumors, and transgenic and orthotopic models for neuroblastoma. He earned his MD and PhD from Boston University School of Medicine, and completed his internship, residency, and fellowship at Baylor College of Medicine.
  • David Steensma, MD

    David Steensma, MD

    David Steensma, MD

    Associate Professor of Medicine

    David P. Steensma, MD, FACP, is an associate professor of medicine at Harvard Medical School, consulting physician at Brigham & Women’s Hospital, and a faculty member in the Division of Hematological Malignancies at Dana-Farber Cancer Institute in Boston, Massachusetts. He earned his MD from the University of Chicago’s Pritzker School of Medicine, and completed an internal medicine internship and residency and a combined hematology-oncology fellowship at the Mayo Graduate School of Medicine in Rochester, Minnesota. Dr Steensma’s primary clinical and research focus is myelodysplastic syndromes, and he maintains an active interest in marrow failure syndromes. He has more than 300 publications in peer-reviewed journals that include the New England Journal of Medicine, Blood, and Leukemia.
  • Gabriela Hobbs, MD

    Gabriela Hobbs, MD

    Gabriela Hobbs, MD

    Instructor in Medicine

    Gabriela S. Hobbs, MD, is an assistant in medicine at Massachusetts General Hospital (MGH) and an instructor of medicine at Harvard Medical School, both in Boston. She earned her medical degree from Mount Sinai School of Medicine in New York, completed an internal medicine residency at Brigham and Women’s Hospital in Boston, and completed a fellowship in hematology and oncology at Memorial Sloan Kettering Cancer Center in New York. Dr. Hobbs joined the faculty at MGH in 2014, where she established a myeloproliferative neoplasms (MPNs) clinic. Her goal as a clinician and investigator is to create a comprehensive MPN clinic and research program, with research focusing on conducting clinical trials for patients with MPNs.
  • Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Harold J. Burstein, MD, PhD

    Medical Oncologist

    Harold J. Burstein, M.D., Ph.D. is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. He additionally has a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber.

    His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the ASCO guidelines on endocrine therapy for breast cancer. Dr. Burstein an Associate Editor for Cancer Education at the Journal of Clinical Oncology.
  • Eric Winer, MD

    Eric Winer, MD

    Eric Winer, MD

    Director, Breast Oncology Center

    Eric P. Winer, MD, is professor of medicine at Harvard Medical School, chief, Division of Women's Cancers, the Thompson Chair in Breast Cancer Research, and chief clinical strategy officer at Dana-Farber Cancer Institute. He is the leader of the Dana-Farber/Harvard Cancer Center Breast Program, and is the principal investigator/director of the Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer. Dr Winer has designed and led phase I, II, and III clinical trials, and collaborates closely with psychosocial researchers, health services researchers, and basic and translational scientists. His group at Dana-Farber conducts a broad array of breast cancer research with the goal of extending the lives of individuals with breast cancer, and minimizing suffering and morbidity from the disease.